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Abstract
Background: Genital chlamydia infection is the most commonly diagnosed sexually transmitted infection in the UK. C.
trachomatis genital infections are usually caused by strains which fall into two pathovars: lymphogranuloma venereum
(LGV) and the genitourinary genotypes D–K. Although these genotypes can be discriminated by outer membrane protein
gene (ompA) sequencing or multi-locus sequence typing (MLST), neither protocol affords the high-resolution genotyping
required for local epidemiology and accurate contact-tracing.
Principal Findings: We evaluated variable number tandem repeat (VNTR) and ompA sequencing (now called multi-locus
VNTR analysis and ompA or ‘‘MLVA-ompA’’) to study local epidemiology in Southampton over a period of six months. One
hundred and fifty seven endocervical swabs that tested positive for C. trachomatis from both the Southampton
genitourinary medicine (GUM) clinic and local GP surgeries were tested by COBAS Taqman 48 (Roche) PCR for the presence
of C. trachomatis. Samples tested as positive by the commercial NAATs test were genotyped, where possible, by a MLVA-
ompA sequencing technique. Attempts were made to isolate C. trachomatis from all 157 samples in cell culture, and 68
(43%) were successfully recovered by repeatable passage in culture. Of the 157 samples, 93 (i.e. 59%) were fully genotyped
by MLVA-ompA. Only one mixed infection (E & D) in a single sample was confirmed. There were two distinct D genotypes for
the ompA gene. Most frequent ompA genotypes were D, E and F, comprising 20%, 41% and 16% of the type-able samples
respectively. Within all genotypes we detected numerous MLVA sub-types.
Conclusions: Amongst the common genotypes, there are a significant number of defined MLVA sub-types, which may
reflect particular background demographics including age group, geography, high-risk sexual behavior, and sexual
networks.
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Introduction
Genital chlamydia infection is the most frequently diagnosed
sexually transmitted infection in the UK. The number of infected
individuals with chlamydia identified through testing continues to
increase annually (http://www.hpa.org.uk/Topics/InfectiousDi
seases/InfectionsAZ/STIs/STIsAnnualData/AnnualSTISlideset/).
C. trachomatis is traditionally divided into at least 15 ‘serovars’ which
are linked to different disease pathologies. As the majority of women,
and a significant proportion of men, diagnosed with this infection
are asymptomatic, there is a large pool of prevalent undiagnosed
infection which provides a reservoir for further spread (http://www.
bashh.org/guidelines). The spread of infection is determined by
patterns of sex partner selection, the relative risk of infection is
associated with particular social networks and the existence of bridge
populations [1]. Genital chlamydial infections are caused by two
‘pathovars’: lymphogranuloma venereum (LGV: L1,L2 and L3 -
invasive and disseminating) and infections associated with serovars
D to K, which are non-invasive and can cause epididymitis,
cervicitis, urethritis, salpingitis and pelvic inflammatory disease [2].
Sequelae following infection can be severe, such as infertility in
women (including pelvic inflammatory disease and ectopic preg-
nancy) (http://www.bashh.org/guidelines).
Standard multi-locus sequence typing (MLST) approaches which
target a limited number of relatively stable and non-selected loci such
as house-keeping genes [3,4] have been developed for global
surveillance and show a medium-level resolution across all
chlamydia strains at the genotype/serovar level. But MLST as
performed by Pannekoek et al [3] is insufficiently discriminating to
resolve closely related C. trachomatis isolates. An example of the
limited resolution of MLST is the grouping of LGV strains
(belonging to serovars L1, L2 and L3) to a single cluster of identical
MLST-type using the scheme of Pannekoek et al [3], which was
developed using a small number of European isolates and the two
complete published genomes available at the time [5,6]. The more
recent MLST scheme developed by Dean et al [4] is only able to
discriminate L2b (the proctitis-causing variant of L2) from the rest of
the LGV group, and does not discriminate between L1, L2 and L3.
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However, the purpose of MLST schemes in highly homogeneous
bacterial populations is to describe population structure and
diversity, and not to operate at the level of an ultimate strain typing
scheme [7]. There is growing evidence of a small but meaningful
variation at the genome level [8], therefore methods of high
resolution genotyping are required to reveal more discriminating
data. Such data is important for the monitoring of therapy and
contact tracing including route-cause analysis, and study of sexual
networks.
An ‘‘MLST’’ system has been described [9] that shows some
promise for discriminating strains, however this does not follow the
rules of MLST (exclusive use of housekeeping genes and small
amplicons), therefore this should really be considered as multi-
sequence typing (MST). There has been only one attempt at
developing rapid, high resolution genotyping [10], which targets
short, mutable sequences and thus facilitates detailed resolution of
local diversity at high efficiency in short periods of time (the latter
incorporating variable number tandem repeat (VNTR) analysis).
VNTRs are repetitive sequences of the same nucleotide or motif,
and variation in DNA polymerization errors in different strains
gives rise to variation in length between strains [10]. Multi-locus
VNTR analysis (MLVA) of C. trachomatis VNTR sites and ompA
appeared to facilitate a highly discriminatory genotyping survey of
C. trachomatis from clinical samples from Aarhus in Denmark [10].
To evaluate this scheme unbiased, the MLVA-ompA approach
previously (and incorrectly) called ‘‘omp1-VNTR’’ [10] requires
independent analysis on clinical samples in other laboratories. The
original Aarhus study [10] which utilizes four PCR targets
returned data for all samples collected, whereas most studies are
only successful in analyzing a percentage of samples collected, and
the scheme has not been assessed independently using routine
clinical samples to study epidemiology in a typical host population.
This scheme has been compared to the MLST scheme of
Pannekoek et al [3] and the MST scheme of Klint et al [9] in a
retrospective study of a small number highly selected set of samples
which had been cell-culture adapted in Moscow collected in 2005
[11]. Amplification conditions were highly optimized as the
chlamydial DNA was prepared from semi-purified elementary
bodies: the approach in the Moscow study is therefore not
applicable to routine clinical samples.
Our aim was to evaluate independently the MLVA-ompA
approach. To facilitate this we used routine clinical swab samples
from women in the local C. trachomatis diagnostic laboratory to test
the success rate of MLVA-ompA analysis for all four markers. Our
selection of samples positive for C. trachomatis was a commercial
nucleic acids amplification technology (NAAT) test (COBAS
Taqman 48, Roche) which uses highly conserved DNA targets.
The fact that only swabs were collected resulted in men being
excluded from this survey, because in the case of the COBAS
Taqman 48 (Roche) system urine samples can also be processed and
this is the preferred sample chosen by men. Therefore the study in
Southampton was limited to women. Our approach resulted in a six
month survey in which primary swab samples from women paired
with DNA extracts with commercial NAATs C. trachomatis positive
results were collected, cultured and genotyped. A far greater
diversity in MLVA-ompA genotypes in comparison to using ompA
alone was found in our sample set including a new genotype (which
was a J variant) that could not be isolated in cell culture.
Materials and Methods
Clinical samples
Endocervical swabs collected between February and July 2009
from patients presenting at the GUM clinic in Southampton, and
also samples referred from GP surgeries were analyzed for the
presence of C. trachomatis using the commercial NAAT incorpo-
rating the Tecan DNA extraction system and COBAS Taqman 48
(Roche) real-time PCR protocol in the Health Protection Agency
(HPA) Molecular Diagnostics Laboratory, Southampton. Crude
DNA extraction, real-time PCR and analysis were performed
according to the manufacturer’s instructions. DNA extracts, which
gave ‘‘strong’’ positive results according the cycle threshold (CT,
or = 30), were processed for high resolution genotyping as
described below. The primary swab sample from which the
DNA extract was made was retained, so that the transport
medium (M4RT) could be used to inoculate tissue culture for
isolation of live C. trachomatis. Although this real-time PCR
protocol is not a validated quantitative assay, the CT values of
positive extracts were taken to indicate a reasonable level of C.
trachomatis carriage in that sample for use in further PCR and
sequence analysis as well as having a reasonable likelihood of
providing a culturable inoculum. As an additional criterion to
qualify for the latter process, we excluded swab samples and their
paired DNA extracts that were.3 days old from time of sampling,
as samples older than this did not usually contain culturable
inocula. DNA extracts were stored at 280uC prior to MLVA-
ompA analysis. The paired transport medium samples were stored
at 4uC for ,4 days following collection prior to isolation in cell-
culture. Approval by ethical committee and patient consent were
not obtained as this was considered a standard evaluation of an
existing method. Furthermore the samples that we used had been
discarded following routine diagnostic analysis, and they were
unlinked and anonymised so as to permanently protect patient
confidentiality.
Culture of isolates
The transport medium (M4RT) contained gelatin, gentamicin,
and amphotericin B, and although specifically designed for
transport and long term storage of viral specimens, we investigated
the potential to culture C. trachomatis isolates directly from the
clinical swabs rather than collect separate swabs for the specific
purpose of this study, so as to maintain a collection of local isolates
and facilitate further in-depth whole-genome and biological
studies. This was possible because M4RT is designed to preserve
organism integrity rather than act as a precursor to lysis, which
occurs with some other commercial systems. It should be clarified
that we defined the ability of an isolate from a sample to be
cultured as being capable of at least two growth-passages through
tissue culture, visible at each stage as inclusions by phase contrast
microscopy, thus enabling a perpetuated collection of local isolates
which may be used in future studies.
A 24–well tray of McCoy cells was prepared the day before
infection. For infection, the cell culture medium was removed
from the cells and 1 ml of the transport medium containing
potential C. trachomatis isolates was added to a well. The 24–well
tray was then centrifuged at 7546g for 30 min to facilitate
infection. The transport medium was then replaced with 1 mL
fresh Dulbecco’s Modified Eagle Medium containing cyclohexi-
mide (1 mg/mL), gentamicin (20 mg/mL), and vancomycin
(10 mg/mL), and the cells incubated at 37uC for 72 h. After
incubation, if any viable C. trachomatis isolates were present they
could be viewed by light microscopy as inclusion bodies. Positive
samples were then scraped up using a sterile pipette tip, mixed
with glass beads for 1 min to break open the host cells, centrifuged
at 1106g for 5 min to remove any cell debris, and then the
supernatant was added to an equal volume of storage buffer (4SP)
and stored at 280uC.
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Amplification of VNTR and ompA sequences
VNTR loci and ompA sequences were amplified by PCR from
the DNA extracts from positive swab samples (as determined by
the COBAS Taqman 48 method) as follows: The ompA gene was
amplified using primers PCTM3 and NRI according to Lan et
al [12] (Table 1). As a contingency, alternative primers
OMPSeqF and OMPSeqR were used which amplified a
718 bp fragment of ompA in cases where PCR of the 1,019 bp
amplicon proved not possible (Table 1). Sequences encompass-
ing the three VNTR loci were amplified using primers CT1291F
and R, CT1299F and R and CT1335F and R according to
Pedersen et al [10] (Table 1). The PCR reaction components
were: 16HF buffer, 200 mM each of dioxynucleotriphosphates
G, A, T and C, 250 nM each of forward and reverse primers
(Table 1), 2–4 ml of DNA sample, 0.5 ml of Phusion High-
Fidelity DNA polymerase (New England Biolabs UK, Hitchin,
UK), and H2O to final volume of 50 ml.
The PCR was performed using the Veriti 96 well Thermal
Cycler (Applied Biosystems International, Warrington, UK). The
general PCR program was: 2 min at 98uC, followed by 35–40
cycles of 20s at 98uC, 30 s at 56–64uC and 45 s at 72uC, with a
final extension step of 7 min at 72uC, and then held at 16uC. For
ompA PCR, 35 cycles and 56–58uC annealing temperature were
used. The PCR completed forty cycles for the VNTRs; the
annealing temperatures were 56–59uC for CT1291 and CT1335,
and 62–64uC for CT1299. The PCR products were purified using
Wizard SV Gel and PCR Clean-up System (Promega, South-
ampton, UK).
Sequencing
Sequencing reactions on purified PCR products were carried out
by a commercial company: Gene Service (http://www.geneservice.
co.uk). The sequencing primers for CT1291, CT1299 and CT1335
are internal primers CT1291inF, CT1299inR and CT1335inR,
respectively. The sequencing primers for ompA are NR1 (longer
PCR) or OMPSeq2R (shorter PCR) (Table 1).
MLVA-ompA sequence analysis
OmpA sequences were genotyped via comparison to the NCBI
database via BLAST, and sequence types were assigned using
reference strains according to the following strain names and
accession numbers: D, D/UW-3/CX NC 000117; E, E/BOUR
DQ06428; F, F/IC-CAL3 DQ064287; G, G/392 DQ064288; I,
Ia/870 DQ064291; J, J/UW-36 DQ064292; K, K/UW-31
DQ064293.
VNTR sequences were analyzed manually using the original
fluorescent traces and by comparison of the alphabetical sequences
to those of D/UW-3/CX, accession number NC 000117. The
assignment of MLVA-type was carried out according to the rules
described in Pedersen et al [10], namely, a number was assigned to
each different VNTR locus based on the differing number of
mononucleotides. Therefore the three sequenced VNTR loci gave
rise to a corresponding three-digit code according to the order:
CT1335; CT1299 and CT1291. Where new MLVA types were
discovered that were not defined in Pedersen et al [10], we
assigned new numbers which were added to the C. trachomatis
MLVA database (http://www.klinmik.dk/genotyping/MLVA_
types.asp).
Results
Preliminary Pilot study
In December 2008 we began our preliminary primary study,
collecting DNA samples. In the first instance we collected nine
DNA samples during that month. Of these, only seven gave a full
set of amplicons compatible with the VNTR and ompA PCR
products capable of yielding sequence data. Therefore we
concluded that a proportion of our samples in the main study
may not yield full genotyping data. To address this possible loss of
data, we designed a study in which we collected crude DNA
samples paired with the primary swab used to collect the sample,
this swab was preserved in virus transport medium (Micro Test
M4RT Transport medium, Remel, Lenexa, Kansas, USA). From
the latter, we attempted to culture live isolates of the C. trachomatis
Table 1. Primer sequences for PCR of ompA and VNTR loci.
Primer name Primer sequence (59 – 39) Amplicon sizea (bp) Nucleotide positiona Reference
PCTM3 TCCTTGCAAGCTCTGCCTGTGGGGAATCCT 779,977–780,006 Lan et al [12]
NRId CCGCAAGATTTTCTAGATTTC 1,019 778,988–779,008 Lan et al [12]
CT1291F GCCAAGAAAAACATGCTGGT 195,536–195,555 Pedersen et al [10]
CT1291R AGGATATTTCCCTCAGTTATTCG 225b 195,760–195,738 Pedersen et al [10]
CT1299F TTGTGTAAAGAGGGTCTATCTCCA 291,758–291,781 Pedersen et al [10]
CT1299R AAGTCCACGTTGTCATTGTACG 188 29,1945–291,924 Pedersen et al [10]
CT1335F TCATAAAAGTTAAATGAAGAGGGACT 737,225–737,250 Pedersen et al [10]
CT1335R TAATCTTGGCTGGGGATTCA 153 737,377–737,358 Pedersen et al [10]
OMPSeqF GGTGTGACGCTATCAGCATGC 779,880–779,900 This study
OMPSeqR GACCATTTAACTCCAATGTA 718 779,183–779,202 This study
CT1291inFd TACAAAAGTGTTGTGATAATTC - 195,559–195,580 This study
CT1299inRd ACGAATCCTCTAAGTACGG - 291,908–291,926 This study
CT1335inRd GGATTCAACGATGATTAAGG - 737,345–737,364 This study
OMPSeq2Rd TATTGGAAAGAAGCICCTAAc - 779,417–779,436 This study
aaccording to D/UW-3/CX, accession number NC 000117.
ban amplicon of 510 bp was seen in some samples.
cI = inosine.
dPrimers used for sequencing.
doi:10.1371/journal.pone.0016971.t001
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present in the positive swab samples. We found that swab samples
lost viability if more than three days (at 4uC) had elapsed between
time of sample taking and receipt following confirmation of
positivity. This contingency would allow us to extract DNA from
cultured isolates and enable genotyping analysis data to be added
to the data collected from the crude DNA isolates.
Clinical samples
In the six month period between February and July 2009 a total
of 5339 female swab specimens were submitted to the HPA
laboratory and from these 268 (4.9%) provided a positive result.
From these 268 there were 111 positive samples that did not meet
our inclusion criteria leaving 157 paired positive DNA extracts
with swab samples which did comply with our sampling criteria.
From these 157, 46 samples originated from GP surgeries and the
other (111) samples originated from the GUM clinic. The age
distribution of the samples demonstrated most specimens occurred
in patients who were 16–24 years of age (117/157, with a median
of 20 years of age in the 16–24 range; Table 2).
MLVA-ompA sequence analysis
Prior to this study we tested a collection of Taq DNA
polymerase types, and due to its high fidelity concluded that we
should use Phusion Taq DNA polymerase (New England Biolabs
UK, Hitchin, UK) for all PCR reactions. This is a high fidelity
enzyme which we employed for several reasons, including to
eliminate the possibility of PCR error in amplification of tandem
repeats of monothymidines of greater than eleven base-pairs [13].
Direct genotyping from the DNA extracts used for the NAAT test
that deployed the three VNTR loci and ompA was possible for 85 of
the samples. The ompA sequences were aligned with 18 known
reference ompA sequences from the GenBank sequence database
[14]. The genotypes which most regularly produced a positive
genotype were; D, E and F, comprising 20.4%, 40.9% and 16.1%
of the genotyped positives respectively (Figure 1). Genotype D
could be sub-divided into two divergent types by comparing the
differing sequences available on the NCBI database. Therefore the
proportion that were genotype D (20.4%) comprised 11.8% of the
total which aligned with D/UW-3/CX, and 8.6% of the total
which aligned with D/IC-CAL3. No genotype H was found.
Isolates were cultured (i.e. were capable of at least two passages
through tissue culture) from 68 of the paired M4RT samples that
originated as primary swab samples; 49 of these were amongst the
85 that were directly genotyped (see Table S1 for full results). All of
the 89 samples that were classed as non-culturable did not show
any growth in tissue on the primary passage. Of the 68 samples
which were subsequently found to be culturable, use of the
MLVA-ompA typing scheme on the primary DNA samples allowed
us to identify 26 distinct types including six of genotype D; nine of
genotype E; four of genotype F; four of genotype G; three of
genotype Ia; and one each of J and K. Of the 19 samples that were
not directly genotyped but were cultured, it was possible to extract
DNA and fully genotype 8 samples (the incomplete data for all 19
isolates is shown in Table S2). To achieve this, we had to use the
‘‘short fragment’’ PCR and sequencing option because no result
was obtainable using the long fragment option. Only where we
could attain good quality sequence data for variable domains II
and IV of ompA did we accept the identification data as accurate.
Therefore we gained a further eight of nineteen cultured samples
to add to our total of MLVA-ompA genotyped collection.
Consequently we returned a total of 93 fully MLVA-ompA
genotyped samples. The age-distribution of the 93 specimens
analyzed by MLVA-ompA was similar to that of the 157 total
specimens received, in that most specimens occurred in the
patients 16–24 years of age (Table 2).
Of the 93 fully genotyped specimens, six profiles appeared to
have a multiple (mostly two) of VNTR sequences in one sample
(Table S3), i.e. sequence data suggested the presence of more than
one VNTR type at the same locus in these samples (evidenced by a
succession of two nucleotides detected at the same point on the
sequencing chromatogram). In one specimen, a mixed infection
according to the ompA sequence was suspected. In this case, the
ompA gene was cloned and sequenced, revealing that this sample
contained genotypes E and D/UW-3/CX. Isolates that were
cultured then genotyped belonged to genotypes D, F, G, J and K
(Figure 1).
Throughout the analysis of ompA, various nucleotide polymor-
phisms in comparison to database/known sequences were noted
(see Tables S4 and S5). Of the four genotype J samples, two had
twelve identical nucleotide changes in the ompA sequence
compared with J/UW-36 . Ten mismatches distinguished D/IC-
CAL8 from D/UW-3 (data not shown).
There were different MLVA types within each genotype,
including the two genotype D variants (Figure 2). Overall, the
combination of the ompA and MLVA as a genotyping panel gave,
for this set of results, a Simspon’s discriminatory index [15] of
0.96. Of the eight samples which could only be genotyped
following culture (Table S3), five (MLVA-ompA types: 3.2.4-K;
3.6a.3-D/UW-3; 12.5a.2-G; 3.4a.2-J; and 8.8.2-F) were unique
genotypes which had no replicates that were also detectable
directly from the original DNA samples. Some MLVA signatures
were common to different ompA types, for example 8.5.2 was
found in ompA types D (both sub-types), E, F and J; whilst 8.6.2
was found in D/IC-CAL8, E, and F. In most cases however,
MLVA signatures were unique to ompA types. As well as defining
some new VNTR sequences for the three loci (Table 3), we further
noted that in some cases there were differences in the flanking
regions between two samples where the VNTR locus sequence
itself was identical. For example, VNTR CT1299 variant 4
(Table 3) has a tandem repeat of ten cytosine residues (10C). In
our survey, we found three versions of CT1299 variant 4 with
10C, with three different sequences between the conserved
flanking regions, namely 10C (variant 4), 10C-T3C (variant 4a)
and CT-10C-T3C (variant 4b). We therefore extended the
signature numbering system of Pedersen et al [10] to enable
differentiation by inclusion of the eight-base flanking regions. Two
samples which were genotypes E and J, had a new CT1299 variant
(which we have designated as variant 9; Table 3). This variant is
common in LGV strains, which may indicate a closer linkage of
particular genital tract strains to LGV than others.
For each sample, locusCT1291 PCRmostly produced either of two
different amplicon sizes (,225bp or ,510bp), the former amplicon
being common to genotype E samples. CT1291 variant 1 (Table 3)
was exclusively found in the ,510bp amplicons. CT1291 is found
within a gene coding sequence and this variation may represent a
significant difference in lineages associated with variant 1 which has a
Table 2. Distribution of samples tested (n = 157) according to
age and GUM clinic or GP referral.
Age range (years) GUM GP referral GUM as % of total Total
16–24 92 25 79 117
25+ 19 21 48 40
Total 111 46 71 157
doi:10.1371/journal.pone.0016971.t002
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large indel site between the primer-annealing sites in comparison to
the variants found in the ,225bp amplicons. Furthermore, one
sample displayed evidence of deletion of locus CT1291.
Of the two different sizes of CT1291 PCR products (,225bp or
,510bp), the 225bp fragment aligned with the downstream half of
the ,510bp fragment. All ,510bp PCR products had the same
variant (variant 1; Table 3) - most found in genotype E (32 out of
34 CT1291 variant 1 samples). One sample failed to generate a
VNTR sequence despite amplification of a ,280 bp amplicon.
Sequence analysis revealed this amplicon to have a sequence
Figure 1. Distribution of ompA types discriminated according to whether they were genotyped directly from clinical samples,
whether any of these were subsequently cultured, and those that could only be genotyped following culture (n=93).
doi:10.1371/journal.pone.0016971.g001
Figure 2. Distribution of different VNTR types according to ompA genotype (where loci appeared mixed in individual samples, both
numerals are given separated by a ‘/’).
doi:10.1371/journal.pone.0016971.g002
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homologous to the upstream region only of the ,510bp version of
CT1291 PCR products.
Discussion
This study showed that in an urban UK population, there is a
greater genetic diversity among circulating C. trachomatis strains
than can be measured by ompA-based genotyping alone, the
(previous) gold standard for C. trachomatis genotyping. This
revealed a diversity measured by differences in MLVA, but also
showed that there is a diversity of MLVA types unique to specific
ompA genotypes. In addition we noted that there was a diversity of
ompA types found within certain common MLVA types, for
example MLVA type 8.5.2 was distributed between ompA types D
(both sub-types), E, F and J. This strongly suggests evidence of
recombination, i.e. mobility of an element containing ompA
supporting recent observations of Dean et al [4].
This report describes the first independent study of the MLVA-
ompA genotyping scheme applied directly to routine clinical samples
and used as a tool for genotyping in a survey of C. trachomatis-positive
specimen-swabs from women. It also demonstrates that it was
possible to preserve isolates (capable of undergoing more than two
passages in tissue culture) based on using the swab supernatant, giving
an isolation rate of 43%. An estimation of diversity according to
assignment of different genotype by the MLVA-ompA definition
indicates we have at least 26 different live variants (out of 68
culturable isolates in total) as an ongoing collection across the
genotypes D, E, F, G, Ia, J and K. Further genomic analysis of these
and others of the total of 68 culturable isolates may reveal a greater
diversity in this collection, for example it is possible that two isolates
with a MLVA-ompA identity of 8.7.2-F may differ significantly at
other loci. Furthermore, the stability of VNTR loci should be taken
into account when assigning identities. VNTR sequence may vary
over only a few generations, therefore such locimay only be useful for
once-only assessments of local epidemiology and not suitable for
repeated sampling of a population. There is some evidence that these
loci may be stable [10], but this is based upon recurrent or persistent
infections in patients and not using tissue culture to grow defined
generations of a single strain against which to measure stability. The
incidence of genotypes that could only be cultured in this evaluation
(Table S3) raises the possibility that culturing may be selective, and
that certain genotypes are more suited to culture–recovery than
others. The use of swab samples which employ M4RT as the
transport agent for the COBASTaqman 48 (Roche) diagnostics assay
is fortuitous in that the presence of gentamicin is of benefit to
chlamydial tissue culture as it helps control contamination and at the
correct concentrations does not inhibit chlamydial growth [16]. It is
recommended that tissue culture of isolates should be commenced
within 24 hours of collection of a swab sample [17]. In our case, the
time taken to allow delivery of the swabs from the GUM clinic and
GP practices to the HPA Molecular Diagnostics Unit was without a
reliable cold chain which adversely affected our isolation rate.
Furthermore we set high criteria for isolation hence our isolate rate of
43% reflects a realistic figure with routine samples. It may be possible
in future studies to obtain a greater number of isolates by freezing
samples immediately after processing at 280uC so as to increase the
probability of preserving viable elementary bodies.
The high numbers of samples from the 16–24 age-group (79%;
Table 2) reflects the published figures for the UK South Central
Strategic Health Authority (SCSHA) highlighting this to be the
most at-risk age group in Southampton, which has one of the
highest rates of sexually transmitted infections in the country
(hpa.org.uk). In 2009 there was a 38% increase in total C.
trachomatis cases in the SCSHA since 2000, and of the 3028 female
cases in this region, 2286 fell within the 16–24 age-group.
The sampling algorithm meant that it was likely that swabs with a
large load of target were mainly taken. This may have had the affect
that samples arose from a proportion of the infected population
which sheds large numbers of EBs, possibly symptomatic. Although
the algorithm in this study was designed to ensure culturable
samples, future high resolution genotyping studies should focus on
DNA alone and thus bacterial load will be irrelevant, allowing more
samples from asymptomatic patients to be collected.
The distribution of ompA genotypes was similar to that found in a
survey of this marker in the UK (Cambridge) in that E was the most
Table 3. VNTR sequence analysis and description of
previously unseen VNTR types.
VNTR type code (including
new & modified) CT1335 Variantsa
1 GAAAAAG-9T8A-GCTTTTGT
3 GAAAAAGG-10T8A-GCTTTTGT
3a (modified) GAAAAAAG-10T8A-GCTTTTGT
5 GAAAAAG-11T8A-GCTTTTGT
6 GAAAAAGG-12T7A-GCTTTTGT
7 GAAAAAGG-12T8A-GCTTTTGT
8 GAAAAAGG-13T7A-GCTTTTGT
9 GAAAAAGG-13T6A-GCTTTTGT
11 (new) GAAAAAAG -7T9A-GCTTTTGT
12 (new) GAAAAAAG -8T9A-GCTTTTGT
13 (new) GAAAAAGG-9T9A-GCTTTTGT
CT1299 Variantsa
1 TTTTTATTCT-7C-ATCAAA
2 TTTTTATTCT-8C-ATCAAA
3 TTTTTATTCT-9C-ATCAAA
3a (modified) TTTTTATTCT-9C-T3C-ATCAAA
4 TTTTTATTCT-10C-ATCAAA
4a (modified) TTTTTATTCT-10C-T3C-ATCAAA
4b (modified) TTTTTATTCT-CT-10C-T3C-ATCAAA
5 TTTTTATTCT-11C-ATCAAA
5a (modified) TTTTTATTCT-11C-T3C-ATCAAA
6 TTTTTATTCT-12C-ATCAAA
6a (modified) TTTTTATTCT-12C-T3C-ATCAAA
7 TTTTTATTCT-13C-ATCAAA
8 TTTTTATTCT-14C-ATCAAA
9 (new) TTTTTATTCT-3C2T-6C-ATCAAA
CT1291 Variants Variantsa
1 AAAATGGTCTA-6C-TATTG **
2 AAAATGGTCT-8C-TATTG
2a (modified) AAAATGGTCTA-8C-TATTG
2b (modified) AAAATAGTCTA-8C-TATTG***
3 AAAATGGTCT-9C-TATTG
4 AAAATGGTCT-10C-TATTG
5 AAAATGGTCT-11C-TATTG
6 (new) AAAATGGTCT-CT-5C-TATTG
7 (new) AAAATGGTCT-12C-TATTG
aVNTR region shown in bold.
Flanking region variations underlined.
doi:10.1371/journal.pone.0016971.t003
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common genotype detected, and D and F were the next most
common genotypes [18]. Interestingly, the Cambridge survey also
reported no genotype H detectable from females. The abundance of
genotypes D, E and F reflects many studies [19–21]. By contrast,
Ikryannikova et al [11] showed the most abundant ompA genotypes
to be E, G and K. This most likely reflects the very small sample size
and the pre-selection of only culture-adapted strains. Culture-bias is
known to underestimate certain strains in epidemiological studies,
especially in difficult-to-culture pathogens [22].
Only one sample in our study was found to represent a mixed
infection (i.e. more than one different genotype in the same
sample), confirmed by cloning the amplicons into vectors and
analyzing the sequences of the two separate clones obtained. The
mixed infection proved to consist of genotypes equivalent to
laboratory C. trachomatis strains D/UW-3 and E/Bour.
Comparison of C. trachomatis genomes has demonstrated that
different chlamydia strains share .99.5% sequence identity
[5,23], therefore sequence differences are often apparent between
different isolates only at the single nucleotide level. MLVA has
many advantages for epidemiological studies of bacterial patho-
gens with highly conserved genomes [24]. The strength of MLVA
is that it targets single, or small-number, nucleotide deletions or
insertions in the tandem repeat locus. This allows for high
definition differentiation between isolates in monomorphic
bacterial populations but it does not indicate evolutionary
relationships [25]. However, in the case of C. trachomatis
epidemiology, MLVA helped ascertain that whilst infected
partners may appear to have the same strain owing to mutual
transmission according to ompA analysis, MLVA data showed that
one partner could have the same ompA type but a different MLVA
type, indicating links to infection outside the partnership post-
mutual transmission [10]. A weakness of MLVA is that it
effectively relies on ‘‘mistakes’’ made by the host DNA polymerase
during replication, therefore although useful in a localized survey
covering a selected time-period, drift in tandem repeat insertions
or deletions (indels) in the same C. trachomatis strain may reveal
disparities when comparing surveys taken at different times from
the same population. A key factor in our experimental design was
the choice of a high quality, high fidelity thermostable polymerase
therefore we have very high confidence in the sequencing results.
Our diversity index value for the MLVA-ompA scheme (0.96)
reflects that measured by Ikryannikova et al [11] when combining
the three VNTR markers and ompA. In our survey, although we
observed a wide diversity of MLVA types particularly in genotype
E, there may be drift (e.g. plus or minus one nucleotide of the
VNTR) in the locus represented by the middle digit of the MLVA
code. For example there were a number of results for VNTR locus
CT1299 suggesting this might be a site which undergoes variation
with replication of a single clone. This was manifested in samples
which appeared to be single infections according to pure sequence
data for three of the four loci, but with one locus showing evidence
of several sequence variants within the tandem repeat. This was
confirmed by cloning and sequencing VNTR amplicons where
this phenomenon was apparent. An example of the results showed
the presence of both 9C and 10C loci occurring in a sample with
otherwise identical remaining loci. Examples of such single-locus
mixed variants were found in all three VNTR loci. This could
either represent genuinely different VNTR sequences, or the same
VNTR sequence in the Southampton population experiencing
drift of the middle locus (i.e. it is possible that the VNTR sequence
in the same strain may vary by minus or plus one nucleotide with
different generations). Several MLVA-ompA genotypes were
present in large clusters indicating specific sexual transmission
networks, for example there were twelve samples that were 8.5.1-
E, seven 8.6.2-F, and seven 8.5.2-D/IC-CAL8 (Figure 2 and
Table S3). These may represent interesting clusters of cases, that
might indicate specific sexual networks in terms of lines of
transmission. Future studies that would allow demographic data to
be collected along with the samples may be able to answer
questions regarding contact tracing (which is acknowledged as only
allowing an incomplete picture of a network due to its reliance on
verbal cooperation of patients [26]) using analysis of such clusters.
There are several important uses for being able to type C.
trachomatis to a high definition once an acceptably sensitive and
robust genotyping panel is available: Partner notification in tracing
transmission patterns in sexual networks; connection of clinical
presentation and pathogenicity to genotypes; organ and tissue
tropism association with genotypes; aiding forensic investigations;
discrimination of persistent infections [10] epidemiology and
detection of emerging strains. To establish a reliable high
resolution genotyping system, the first step is to test the system
against a local population to review the fidelity of resolution [26].
Although not specified by our experimental design, all the
samples were from women, most probably attributable to swabs
being unpopular amongst men attending UK GUM clinics. The
genotyping system deployed sequence analysis of the ompA gene
and three VNTR loci. Although recent evidence reveals that ompA
may be more mobile than previously thought [4], it remains a
useful target as part of a panel of markers as in the present study
because there is a limited resource of database information
encompassing all possible genome-based markers for genotyping
and ompA genes have been the most studied in terms of C.
trachomatis epidemiology. The use of a small number of markers
(e.g. three for VNTR) is limiting for investigating phylogenetic
relationships between strains, and whilst programmes such as
eBurst (http://eburst.mlst.net/) have been used the analyses
appear to be of limited use [11]. However, the value of the
current MLVA-ompA scheme seems significant based on this and
other studies [10,11] which have shown its value in determining a
greater diversity in C. trachomatis populations than measured by
ompA alone. Therefore further investigation and development
work is required to identify more VNTR markers. High
throughput analysis of chlamydia genome sequences may be the
ultimate way of generating data for in-depth studies but there
remain considerable challenges with this technology and sample
quality [27]. A better intermediate typing scheme with greater
resolution and strain definition may be possible without the need
for complete genome sequencing if the target panel is increased
and/or altered to include new loci including meaningful SNPs and
markers from other schemes additional to VNTRs. Based on
similar criteria the new J samples should be considered a new ompA
genotype J subtype.
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Table S1 Data for directly sequenced samples (n = 85). The
samples from which C. trachomatis was isolated are highlight in
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Table S2 A: Sequencing results from 19 culturable C. trachomatis
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